Steven J. Meyer
Director of Finance/CFO en JVM Capital LLC .
Perfil
Steven J.
Meyer's current job(s) include being the Chief Financial Officer at JVM Capital LLC since 2005 and the Chief Investment Officer at Jvm Realty Corp.
since 2018.
Formerly, Mr. Meyer served as the Chairman at INSYS Therapeutics, Inc. from 2017 to 2019, Independent Director at Akorn, Inc. from 2009 to 2020, Director at InSys Therapeutics, Inc. from 2007 to 2011, Director at Insys Pharma, Inc. from 2007 to 2010, and Treasurer & Vice President-Global Operations at Baxter International, Inc. from 2004 to 2004.
Mr. Meyer obtained an MBA from Kellogg School of Management and an undergraduate degree from the University of Illinois At Urbana–Champaign.
Cargos activos de Steven J. Meyer
Empresas | Cargo | Inicio |
---|---|---|
JVM Capital LLC
JVM Capital LLC Investment ManagersFinance JVM Capital LLC provides investment advice. The private company is based in Oak Brook, IL and has subsidiaries in the United States. | Director of Finance/CFO | 04/08/2009 |
Jvm Realty Corp. | Chief Investment Officer | 04/04/2018 |
Antiguos cargos conocidos de Steven J. Meyer.
Empresas | Cargo | Fin |
---|---|---|
AKORN, INC. | Director/Board Member | 01/10/2020 |
INSYS THERAPEUTICS, INC. | Chairman | 05/06/2019 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Director/Board Member | 02/05/2011 |
Insys Pharma, Inc. | Director/Board Member | 01/11/2010 |
BAXTER INTERNATIONAL INC. | Chief Operating Officer | 01/07/2004 |
Formación de Steven J. Meyer.
Kellogg School of Management | Masters Business Admin |
University of Illinois At Urbana–Champaign | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BAXTER INTERNATIONAL INC. | Health Technology |
Empresas privadas | 6 |
---|---|
Akorn, Inc.
Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL. | Health Technology |
JVM Capital LLC
JVM Capital LLC Investment ManagersFinance JVM Capital LLC provides investment advice. The private company is based in Oak Brook, IL and has subsidiaries in the United States. | Finance |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Health Technology |
INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
Insys Pharma, Inc. | |
Jvm Realty Corp. | Finance |
- Bolsa de valores
- Insiders
- Steven J. Meyer